Skip to main content
    A

    Axsome Therapeutics Inc (AXSM)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $141.69
    -2.68 (-1.86%)

    Market Cap: $7.45B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Axsome Therapeutics Inc (AXSM) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Axsome Therapeutics are Apogee Therapeutics, Inc. Common Stock (APGE), TG Therapeutics (TGTX) and Xenon Pharmaceuticals (XENE). By market cap, Axsome Therapeutics ranks 9th of the 13 companies on this page; Halozyme Therapeutics (HALO) is the largest at $11.43B. The median P/E of the 3 companies with a P/E is 27.7x.

    Peer Comparison

    AXSM's ROIC of -48.1% is above the peer median of -74.3%, and its revenue growth of 51.9% is above the median of 0.0%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Axsome Therapeutics (AXSM)$7.45BN/A8.6x-18.2%-48.1%51.9%0.00%
    Apogee Therapeutics, Inc. Common Stock (APGE)$10.22BN/AN/A0.0%N/A0.0%0.00%
    TG Therapeutics Inc (TGTX)$9.75B87.2x11.1x11.8%11.0%60.7%0.00%
    Xenon Pharmaceuticals Inc (XENE)$3.98BN/AN/A0.0%N/A-100.0%0.00%
    Abivax SA American Depositary Shares (ABVX)$7.67BN/AN/A0.0%-159.6%-6.8%0.00%
    Spyre Therapeutics Inc. (SYRE)$9.88BN/AN/A0.0%N/A0.0%0.00%
    Praxis Precision Medicines Inc (PRAX)$9.17BN/AN/A0.0%N/A1349.0%0.00%
    Summit Therapeutics PLC (SMMT)$11.32BN/AN/A0.0%N/A-100.0%0.00%
    Protagonist Therapeutics Inc (PTGX)$8.55B27.7x15.8x62.0%N/A5724.0%0.00%
    Kodiak Sciences Inc (KOD)$7.27BN/AN/A0.0%-1481.8%0.0%0.00%
    Edgewise Therapeutics Inc (EWTX)$5.03BN/AN/A0.0%N/A0.0%0.00%
    Dianthus Therapeutics Inc. (DNTH)$5.17BN/AN/A0.0%N/A205.6%0.00%
    Halozyme Therapeutics Inc (HALO)$11.43B17.8x6.1x26.9%15.8%39.2%0.00%
    Peer median$8.86B27.7x11.1x0.0%-74.3%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Axsome Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Apogee Therapeutics, Inc. Common Stock (APGE)
    Apogee Therapeutics, Inc., through its subsidiary, is a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD)...
    TG Therapeutics Inc (TGTX)
    TG Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the acquisition, development...
    TGTX competitors
    Xenon Pharmaceuticals Inc (XENE)
    Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, is dedicated to developing therapies to treat patients with neurological disorders...
    XENE competitors
    Abivax SA American Depositary Shares (ABVX)
    Abivax SA is a clinical-stage biotechnology firm focused on pioneering immunotherapies for chronic inflammatory diseases and viral infections.
    ABVX competitors
    Spyre Therapeutics Inc. (SYRE)
    Spyre Therapeutics, Inc., a biotechnology company, focuses on advancing a pipeline of antibody therapeutics for the treatment of inflammatory bowel disease by...
    SYRE competitors
    Praxis Precision Medicines Inc (PRAX)
    Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal...
    PRAX competitors
    Summit Therapeutics PLC (SMMT)
    Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and markets drugs to treat infectious diseases in the United States, Latin America...
    SMMT competitors
    Protagonist Therapeutics Inc (PTGX)
    Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical...
    PTGX competitors
    Kodiak Sciences Inc (KOD)
    Kodiak Sciences Inc., a clinical-stage biopharmaceutical company, is dedicated to researching, developing...
    KOD competitors
    Edgewise Therapeutics Inc (EWTX)
    Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases.
    EWTX competitors
    Dianthus Therapeutics Inc. (DNTH)
    Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company that designs, develops...
    DNTH competitors
    Halozyme Therapeutics Inc (HALO)
    Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally.
    HALO competitors

    Frequently Asked Questions About AXSM

    Who are Axsome Therapeutics' main competitors?

    The companies most similar to Axsome Therapeutics include Apogee Therapeutics, Inc. Common Stock (APGE), TG Therapeutics (TGTX), Xenon Pharmaceuticals (XENE), Abivax SA American Depositary Shares (ABVX) and Spyre Therapeutics (SYRE), listed from the closest match.

    Who is Axsome Therapeutics' biggest competitor?

    Halozyme Therapeutics (HALO) is the largest of the similar companies at $11.43B; Apogee Therapeutics, Inc. Common Stock (APGE) is the closest match by business profile, size, sector and industry.

    How does AXSM stock compare with its competitors?

    AXSM's P/S is 8.6x against a peer median of 11.1x; its net margin is -18.2% against a peer median of 0.0%.

    Which of Axsome Therapeutics' competitors pays a higher dividend?

    Axsome Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Axsome Therapeutics bigger than its competitors?

    No. Axsome Therapeutics is 9th by market cap among the 13 companies on this page; the largest is Halozyme Therapeutics (HALO) at $11.43B.